Skip to content
Inciteful Med

The Biology of ADCA: Why the Brain Changes

Last updated:

Autosomal Dominant Cerebellar Ataxia (ADCA) is primarily caused by genetic repeat expansions, such as CAG repeats, which create toxic proteins that damage brain cells. It is an inherited condition with a 50% chance of being passed to children, and longer repeats often cause earlier symptoms.

Key Takeaways

  • • Most forms of ADCA are caused by a genetic glitch called a repeat expansion, often involving CAG repeats.
  • • These genetic repeats create sticky proteins that clump together and damage Purkinje cells in the brain.
  • • Larger repeat counts are generally linked to earlier onset of symptoms and faster disease progression.
  • • Because ADCA is autosomal dominant, a child of an affected parent has a 50 percent chance of inheriting the mutation.
  • • Genetic counseling is strongly recommended for families considering predictive testing to understand risks and emotional impacts.

Understanding the biology of Autosomal Dominant Cerebellar Ataxia (ADCA) means looking deep into your DNA. Most forms of this condition are caused by a specific type of genetic “glitch” known as a repeat expansion [1]. Think of your DNA like a set of instructions; in these conditions, one particular “word” in those instructions is repeated hundreds or even thousands of times, which eventually disrupts how the brain functions [2].

The Genetic “Stutter”: CAG Repeats

The most common cause of ADCA is a CAG repeat expansion [3]. CAG is a chemical code for an amino acid called glutamine [3]. When your DNA has too many CAG repeats, the protein it creates ends up with an abnormally long “tail” of glutamine. This is why these are often called Polyglutamine (PolyQ) diseases [3][2].

How Repeats Damage the Brain

This long glutamine tail makes the protein “sticky” and prone to misfolding [4].

  1. Aggregation: These misfolded proteins clump together into “aggregates” within your brain cells [5][4].
  2. Cytotoxicity: These clumps are toxic to the cell. They interfere with the cell’s ability to clean itself and can trap other healthy proteins that the brain needs to function [2][6].
  3. Cell Loss: Over time, this toxicity causes the Purkinje cells (vital cells in the cerebellum) to stop working and eventually die, leading to the balance and coordination issues you experience [7][8].

Repeat Length and Your Symptoms

In these conditions, the “dose” of the genetic change matters. Doctors look at your repeat count to understand two main things:

  • Age of Onset: Generally, the longer the repeat expansion, the earlier in life symptoms tend to appear [9][10].
  • Severity: Larger repeats are often associated with a faster progression of symptoms [11][12].

This also leads to a phenomenon called anticipation, where the repeat expansion can actually grow longer as it is passed from one generation to the next, causing symptoms to appear earlier in children than they did in their parents [13][14].

Other Types of Mutations

While PolyQ repeats are common, they aren’t the only cause of ADCA. To see how different mutations affect symptoms, view The Major Types of ADCA Explained.

  • Non-Coding Repeats: Some repeats, like in SCA10 or SCA27B, happen in parts of the DNA that don’t code for protein. These damage the brain by creating toxic RNA or by “turning down” the volume of essential proteins [15][16][17].
  • Point Mutations: In types like SCA14 or SCA28, the problem isn’t a long repeat, but a single “typo” or a small missing piece in the genetic code that breaks a specific protein needed for brain health [18][19].

Implications for Your Family

Because ADCA is autosomal dominant, each child of an affected person has a 50% chance of inheriting the gene mutation [20][21].

  • If a child does not inherit the mutation, they cannot pass it on to their own children.
  • The age at which symptoms start can vary widely, even within the same family.

If you are considering sharing this information with family members, genetic counseling is a vital resource. Counselors can help explain the risks, the benefits and drawbacks of “predictive” testing for relatives without symptoms, and support the family through the emotional process of genetic diagnosis [22][23].

Frequently Asked Questions

What causes Autosomal Dominant Cerebellar Ataxia (ADCA)?
Most cases of ADCA are caused by a genetic mutation known as a repeat expansion. This genetic glitch creates abnormal proteins that clump together and become toxic to the cells in your cerebellum, the part of the brain that controls balance.
What is a CAG repeat expansion?
A CAG repeat expansion is a type of genetic stutter where a specific code in your DNA is repeated too many times. This creates a long, sticky protein that damages brain cells and leads to the balance and coordination symptoms of ADCA.
Does the number of genetic repeats in my test results matter?
Yes, doctors use your exact repeat count to help predict how the condition might progress. Generally, a higher number of repeats is associated with symptoms starting earlier in life and progressing more quickly.
Will my children inherit ADCA?
Because ADCA is an autosomal dominant condition, each child of an affected parent has a 50 percent chance of inheriting the genetic mutation. If a child does not inherit the gene, they will not develop the condition and cannot pass it to their children.
What does genetic anticipation mean for my family?
Anticipation means the genetic repeat expansion can grow longer as it is passed down from parent to child. Because the genetic stutter increases in size, symptoms may start at an earlier age in the next generation.

Questions for Your Doctor

  • • Is my type of ADCA caused by a 'coding' repeat or a 'non-coding' repeat?
  • • What is the exact number of repeats in my genetic test result, and how does that relate to my likely disease progression?
  • • Is there a risk of 'anticipation' in my family line, where my children might experience symptoms earlier than I did?
  • • Does my specific mutation typically involve symptoms outside the cerebellum, such as vision changes or muscle twitches?
  • • Can you refer my family members to a genetic counselor to discuss their risks and testing options?

Questions for You

  • • How do I feel about sharing my genetic diagnosis with my siblings or children?
  • • What are my priorities for future care, knowing that the condition is progressive?
  • • Have I noticed any symptoms in younger relatives that might suggest they should be evaluated?
  • • Do I want to know the specific details of my repeat count, or would I prefer to focus only on symptom management?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Evidence and practices of the use of next generation sequencing in patients with undiagnosed autosomal dominant cerebellar ataxias: a review.

    Novis LE, Spitz M, Jardim M, et al.

    Arquivos de neuro-psiquiatria 2020; (78(9)):576-585 doi:10.1590/0004-282X20200017.

    PMID: 32725052
  2. 2

    The Mechanisms of Nuclear Proteotoxicity in Polyglutamine Spinocerebellar Ataxias.

    Lee D, Lee YI, Lee YS, Lee SB

    Frontiers in neuroscience 2020; (14()):489 doi:10.3389/fnins.2020.00489.

    PMID: 32581673
  3. 3

    Pathogenesis of SCA3 and implications for other polyglutamine diseases.

    McLoughlin HS, Moore LR, Paulson HL

    Neurobiology of disease 2020; (134()):104635 doi:10.1016/j.nbd.2019.104635.

    PMID: 31669734
  4. 4

    Generation of Spinocerebellar Ataxia Type 2 induced pluripotent stem cell lines, CHOPi002-A and CHOPi003-A, from patients with abnormal CAG repeats in the coding region of the ATXN2 gene.

    Maguire JA, Gagne AL, Gonzalez-Alegre P, et al.

    Stem cell research 2019; (34()):101361 doi:10.1016/j.scr.2018.101361.

    PMID: 30611021
  5. 5

    On the distribution of intranuclear and cytoplasmic aggregates in the brainstem of patients with spinocerebellar ataxia type 2 and 3.

    Seidel K, Siswanto S, Fredrich M, et al.

    Brain pathology (Zurich, Switzerland) 2017; (27(3)):345-355 doi:10.1111/bpa.12412.

    PMID: 27377427
  6. 6

    Alleviating neurodegeneration in Drosophila models of PolyQ diseases.

    Long Z, Tang B, Jiang H

    Cerebellum & ataxias 2014; (1()):9 doi:10.1186/2053-8871-1-9.

    PMID: 26331033
  7. 7

    SCA7 Mouse Cerebellar Pathology Reveals Preferential Downregulation of Key Purkinje Cell-Identity Genes and Shared Disease Signature with SCA1 and SCA2.

    Niewiadomska-Cimicka A, Doussau F, Perot JB, et al.

    The Journal of neuroscience : the official journal of the Society for Neuroscience 2021; (41(22)):4910-4936 doi:10.1523/JNEUROSCI.1882-20.2021.

    PMID: 33888607
  8. 8

    Spinocerebellar Ataxia Type 2.

    Scoles DR, Pulst SM

    Advances in experimental medicine and biology 2018; (1049()):175-195 doi:10.1007/978-3-319-71779-1_8.

    PMID: 29427103
  9. 9

    The genetic landscape of spinocerebellar ataxias in Taiwan: Insights from 876 genetically confirmed cases.

    Lan SC, Hsiao CT, Jih KY, et al.

    Parkinsonism & related disorders 2025; (141()):108075 doi:10.1016/j.parkreldis.2025.108075.

    PMID: 41082794
  10. 10

    Autophagy and Polyglutamine Disease.

    Ren H, Hao Z, Wang G

    Advances in experimental medicine and biology 2020; (1207()):149-161 doi:10.1007/978-981-15-4272-5_9.

    PMID: 32671744
  11. 11

    Comparable progression of spinocerebellar ataxias between Caucasians and Chinese.

    Lin YC, Lee YC, Hsu TY, et al.

    Parkinsonism & related disorders 2019; (62()):156-162 doi:10.1016/j.parkreldis.2018.12.023.

    PMID: 30591349
  12. 12

    The S-Factor, a New Measure of Disease Severity in Spinocerebellar Ataxia: Findings and Implications.

    Selvadurai LP, Perlman SL, Wilmot GR, et al.

    Cerebellum (London, England) 2023; (22(5)):790-809 doi:10.1007/s12311-022-01424-1.

    PMID: 35962273
  13. 13

    Clinical and genetic analysis of spinocerebellar ataxia type 7 (SCA7) in Zambian families.

    Atadzhanov M, Smith DC, Mwaba MH, et al.

    Cerebellum & ataxias 2017; (4()):17 doi:10.1186/s40673-017-0075-5.

    PMID: 29214039
  14. 14

    RETINAL MANIFESTATIONS OF SPINOCEREBELLAR ATAXIA TYPE 7 IN TWO CONSECUTIVE GENERATIONS.

    Yip G, Henao M, Huang LL

    Retinal cases & brief reports 2017; (11 Suppl 1()):S86-S89 doi:10.1097/ICB.0000000000000423.

    PMID: 27632585
  15. 15

    The genetic and molecular features of the intronic pentanucleotide repeat expansion in spinocerebellar ataxia type 10.

    Kurosaki T, Ashizawa T

    Frontiers in genetics 2022; (13()):936869 doi:10.3389/fgene.2022.936869.

    PMID: 36199580
  16. 16

    Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset Cerebellar Ataxia.

    Pellerin D, Danzi MC, Wilke C, et al.

    The New England journal of medicine 2023; (388(2)):128-141 doi:10.1056/NEJMoa2207406.

    PMID: 36516086
  17. 17

    In Vivo Expression of an SCA27A-linked FGF14 Mutation Results in Haploinsufficiency and Impaired Firing of Cerebellar Purkinje Neurons.

    Ransdell JL, Brown SP, Xiao M, et al.

    bioRxiv : the preprint server for biology 2024; doi:10.1101/2024.10.25.620253.

    PMID: 39484407
  18. 18

    Neurodegeneration in SCA14 is associated with increased PKCγ kinase activity, mislocalization and aggregation.

    Wong MMK, Hoekstra SD, Vowles J, et al.

    Acta neuropathologica communications 2018; (6(1)):99 doi:10.1186/s40478-018-0600-7.

    PMID: 30249303
  19. 19

    SCA28: Novel Mutation in the AFG3L2 Proteolytic Domain Causes a Mild Cerebellar Syndrome with Selective Type-1 Muscle Fiber Atrophy.

    Svenstrup K, Nielsen TT, Aidt F, et al.

    Cerebellum (London, England) 2017; (16(1)):62-67 doi:10.1007/s12311-016-0765-1.

    PMID: 26868664
  20. 20

    Identification of a novel mutation in the CACNA1C gene in a Chinese family with autosomal dominant cerebellar ataxia.

    Chen J, Sun Y, Liu X, Li J

    BMC neurology 2019; (19(1)):157 doi:10.1186/s12883-019-1381-8.

    PMID: 31291898
  21. 21

    Spinocerebellar ataxia type 10 in Chinese Han.

    Wang K, McFarland KN, Liu J, et al.

    Neurology. Genetics 2015; (1(3)):e26 doi:10.1212/NXG.0000000000000026.

    PMID: 27066563
  22. 22

    Genetic fitness and selection intensity in a population affected with high-incidence spinocerebellar ataxia type 1.

    Platonov FA, Tyryshkin K, Tikhonov DG, et al.

    Neurogenetics 2016; (17(3)):179-85 doi:10.1007/s10048-016-0481-5.

    PMID: 27106293
  23. 23

    Factors Associated with Intergenerational Instability of ATXN3 CAG Repeat and Genetic Anticipation in Chinese Patients with Spinocerebellar Ataxia Type 3.

    Du YC, Ma Y, Shao YR, et al.

    Cerebellum (London, England) 2020; (19(6)):902-906 doi:10.1007/s12311-020-01167-x.

    PMID: 32676850

This page explains the biology and genetics of ADCA for educational purposes only. Your neurologist and genetic counselor are the best resources for interpreting your specific genetic test results and family risks.

Stay up to date

Get notified when new research about Autosomal dominant cerebellar ataxia is published.

No spam. Unsubscribe anytime.